LEXARIA BIOSCIENCE CORP.
NASDAQ: LEXX

INVESTOR CONTACT
Phone: 250-765-6424 ext. 202 ir@lexariabioscience.com

DRUG DELIVERY PLATFORM INNOVATOR

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated **DehydraTECH** with a variety of beneficial molecules in oral and topical formats. **DehydraTECH** has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit **www.lexariabioscience.com**.

2024 Investment Highlights

- **Hypertension:** IND opening study HYPER-H23-1
- **GLP-1 drugs**: Conduct **animal** and **human clinical** studies to examine **DehydraTECH-processed GLP-1 drugs**

DehydraTECH

- **Patented formulation** and dehydration processing method changes how the body detects and absorbs drugs
- **46 patents granted** covering method-of-use, composition-of-matter and medical treatment claims

Patented DehydraTECH Process



1 Combine Active Pharmaceutical Ingredient with Fatty Acid Oil



2 Apply to food / carrier particles

3 Perform dehydration synthesis procedure

4 Render as powder or liquid for use in desired final form factor

DehydraTECH Benefits

✓Speeds up onset

✓Increases bioavailability

✓Improves drug potency

✓Lower dosage

✓Lower cost

DehydraTECH in Published Papers

For more information visit: Lexaria Research

International Journal of Molecular Sciences – *June 2023*
Advances in Therapy – *June 2023*
Cannabis and Cannabinoid Research – *April 2023*
Journal of Personalized Medicine – *June 2022*
Journal of Functional Foods – *November 2023*
Biomedicine & Pharmacotherapy – *June 2023*
Pharmaceuticals – *April 2023*
Biomedicine & Pharmacotherapy – *April 2023*
Advances in Therapy – *September 2019*

PRICE	52 WK RANGE	AVG. VOLUME	SHARES OUTSTANDING	MARKET CAP
$3.05	$0.85 - $6.85	116,242	15.8 M	$48.2 M

LEXARIA BIOSCIENCE CORP.
NASDAQ: LEXX

INVESTOR CONTACT
Phone: 250-765-6424 ext. 202 ir@lexariabioscience.com

DRUG DELIVERY PLATFORM INNOVATOR

DehydraTECH FDA Phase 1b IND Program - Stage 1/2 Hypertension

- Successful pre-IND meeting with the FDA in 2022 with 505(b)(2) NDA regulatory pathway confirmed;
- Received FDA clearance for IND opening study HYPER-H23-1
- Phase 1b randomized, double-blind, placebo-controlled study of the safety, pharmacokinetics, and pharmacodynamics of **DehydraTECH**-CBD for the treatment of stage 1 or 2 hypertension
- Only a handful of other published studies have investigated resting blood pressure impacts of CBD; none have reported sustained reductions except **DehydraTECH**-CBD
- FDA has issued clear guidelines defining the need for new antihypertensives that offer novel modes of action
- Treatment of Stage 1 or 2 hypertensive patients not adequately managed with existing treatments

DehydraTECH for Diabetes and Weight Loss

- Randomized, cross-over, single-dose, Investigator-initiated pilot study in 7 healthy volunteers
- Rybelsus® 7mg tablets vs. **DehydraTECH**-Semaglutide 7 mg compound formulated capsules
- Blood sampled at 18 intervals from T=0 to T=600 min and again at T=24hr post-dose follow up
- Higher blood semaglutide levels / AUC demonstrated throughout the study duration with **DehydraTECH** ($p<0.05$)
- Blood glucose levels lower throughout the study with **DehydraTECH** ($p<0.05$); most notably post prandially
- Enhanced central delivery attributes of **DehydraTECH** contributed to the pronounced GLP-1 effect profile
- Apparent improvements in gastrointestinal tolerability witnessed: Zero instances of moderate nausea/diarrhea with **DehydraTECH**-Semaglutide; moderate nausea (n=2) and moderate diarrhea (n=1) only reported with Rybelsus® treatment
- Detailed overview of Lexaria's 2024 GLP-1/Diabetes and Weight Loss Study Programs





MANAGEMENT

Rich Christopher, CEO

- 30+ years of pharmaceutical/medical device experience
- Former CFO/COO at InVivo Therapeutics, iCAD, Inc., Caliber Imaging and Diagnostics, and DUSA Pharmaceuticals.

John Docherty, M.Sc., President & Director

- Specialist in development of drug delivery technologies
- Former President and COO of Helix BioPharma Corp. (TSX: HBP)
- Named inventor on multiple issued and pending patents